NLRP3 and infection: Interestingly, it was also reported that the inhibition of the NLRP3 inflammasome with NLRP3 inhibitor MCC950 only in the late stages of the infection reduced bacterial burden, while early inhibition increased burden, further highlighting the time-dependent role of inflammasome activation in IAV infection outcomes [43].